Amyris Inc (AMRSQ)

[INFINITI]

Load up

[INFINITI]

Looking good here loaded $$$$

[AJ Freely]

$AMRS - 👆Up 48% Pre-Market/Current Price $0.097
👉Announces Operational & Financial Restructuring to Advance Strategic Transformation
👉Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan
👉$190m Financing Commitment from Foris Ventures

[willlbone]

Bid 2 bits.

[KingofPennies]

I'm out! Nice 2 day gain.

[KingofPennies]

I'm in

[eb0783]

It appears that Amyris bought 49% more of a joint venture, Aprinnova, LLC, of which they now own 99%. Seems a good move but not a needle mover, imo.

https://www.sec.gov/edgar/browse/?CIK=1365916&owner=exclude

https://aprinnova.com/

[eb0783]

So.....does anyone have any idea why AMRS went up almost 20% today and on significantly more volume?

[dtgsanjose]

Was last Thursday's big spike up for about 30 minutes a quick short squeeze, an options expiration play, or somebody accumulating a lot, too quickly, in anticipation of good news? Volume has been high for a few days, and "volume precedes price," at least often, but price remains about where it was after recovery a few weeks ago from seven month slump. I have little new info on the company.

[north40000]

https://invest.ameritrade.com/grid/p/site#r=jPage/https://research.ameritrade.com/grid/wwws/research/stocks/news/article?c_name=invest_VENDOR&docKey=1952-471216c07e8a116425f174cd1f9f0122-08%20Sep%202022

[Mamun21]

Do you know what Amyris is? It is a small bushy tree with compound leaves and white flowers which grows wild in thickets all over the island of Haiti.

[eb0783]

I listened to the call. I liked what I heard. Other than not making a profit right now, I saw no downside at these prices. The future looks good. The new plant is almost on line and their strategy is coming together. I'm fortunate I found out now rather than a while back at a much higher price. Almost everything else I have, other than CDMO is under water. I seem to like a company too early. I got my toe wet here.

[north40000]

I read the earnings report this morning. Perhaps buyers are belatedly enthusiastic about the remainder of the year. The update about Purecane introduction to Walmart stores was interesting. Melo also briefly discussed additional revenue from 2 additional molecules amounting to potential $100-125k/molecule by end of year. Vanilla and vitamin E market remain stable. Brazil fermentation factory was also discussed. I would appreciate your reaction to the report.

[eb0783]

Is there any reason for our large upswing or was it just so over sold that we just couldn't help loading up?

[sukus]

Very interesting video. Amyris has very interesting future I believe with this manufacturing capacity to create high value molecules demanded by customers. Started to add again.

[02opida]

EMERYVILLE, Calif., April 11, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market(TM) technology platform today announced that it has started the commissioning of its new fermentation plant in Barra Bonita, Brazil.

[north40000]

AMRS started commissioning its new fermentation plant in Brazil today. Details below:

https://investorshub.advfn.com/Amyris-Inc-AMRS-20449

"....The greenfield site at Barra Bonita is a strategic investment with which Amyris leads the biotechnology sector with manufacturing at industrial scale. The new plant is strategically located next to the Raizen sugar mill, which is the world's second largest of its kind, ensuring continuity of supply and favorable feedstock economics. Sugar cane is a key feedstock for producing our sustainable ingredients. Brazil ranks number one in global sugar production, and operating costs in Brazil are advantaged compared to the U.S. and Europe. The fermentation plant has a proprietary design with a process tower that is 2-times taller than the company's prior Brotas plant to take full advantage of gravity in its vertical fermentation process. The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products. The site has ample space and infrastructure for future expansion.

There is strong consumer demand for bio-based products. A real shift is occurring across multiple end-markets, including food and personal care. Biotechnology has seen significant investment over the past years. However, the majority of the funding has been applied toward the front of the funnel; gene discovery, genetic pathway modeling and microbe engineering. Little investment has been seen downstream in fermentation process development, scale up and fermentation at scale. The lack of scaled precision fermentation expertise and capacity, and thus the ability to manufacture cost effectively at scale is an impediment to biotechnology making a commercial impact. The sector's capital light approach toward fermentation capacity does not bode well for future success.

"At Amyris we are taking control of our destiny with the Barra Bonita plant," said John Melo, President and Chief Executive Officer. "Industry experts are seeing a significant future gap between supply and demand of fermentation-based products. We set out a strategic path over a decade ago that, beyond being the recognized leaders in the science of biotechnology, we would invest in fermentation process capability and capacity. We have a highly experienced team that combines the art and science of manufacturing at scale all the way from the lab bench to the fermentation tower. We are very proud of the team that has engineered and constructed our new plant in record time and during an unprecedented pandemic. We have started to activate the process control modules and are in the process of testing the instruments and automation protocols to ensure that all systems and components are operating efficiently and safely. We are looking forward to accelerating the commissioning process, including the completion of the sterility hold, with a view to operationalize the plant during the second quarter.".....

[Amrsto1000]

I sold all my cdmo over 30. I've been loading up here from six down to the threes. 3 to 30 was a hell of a gain on cdmo.

There's no doubt we can do the same thing here. Everything is just been put in place to substantially increase margins. We are now selling squalene for $2500 a kilo instead of 50 bucks a kilo. The margin problem is over and we're ahead of schedule and production of several new products. The quality of the products is excellent all that is needed now is to build the brands. That's not going to be difficult because of the quality of the merchandise.

I see clear sailing and at least 38 million shorts that should cover. The rise should be consistent.

I'd say 60 to 90 days to 10.

[westjtter]

Barrons loved this stock at $15.25....hmm how about at under $5?

Once again, the old adage of "do your own research" is very prudent....also, being loved by a high profile financial publication is no guarantee of stock market gains...quite the opposite in this case.

The company has some great technology and now a solid financing package, but they have to quit burning through cash....it is time for proper business execution which means streamlining production and review pricing to ensure the company starts making solid margins and profitability.

They are close, but not sure if this management team has it figured out yet!

[north40000]

https://ih.advfn.com/stock-market/NASDAQ/amyris-AMRS/stock-news/86925212/amyris-and-immunitybio-complete-joint-venture-for

"EMERYVILLE, Calif. and CULVER CITY, Calif., Jan. 3, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, and ImmunityBio (Nasdaq: IBRX), a clinical-stage immunotherapy company, today announced the completion of a previously announced joint venture agreement to accelerate the commercialization of a leading next-generation COVID-19 vaccine.

IB Logo

Amyris and ImmunityBio combine important vaccine technology and manufacturing capabilities in the joint venture. Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second generation vaccine in 2022 as soon as is practically possible with a goal of delivering immunity for COVID-19 and access to underserved parts of the world where current vaccine technology is challenged due to cost and supply chain limitations.

"We are pleased to combine our expertise in human trials, T-Cell technology and our access to RNA manufacturing capacity with the Amyris and Infectious Disease Research Institute (IDRI) RNA technology platform and Amyris' adjuvant technology," said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. "Combined we have a real opportunity to provide true immunity against COVID-19 variants along with a platform that can quickly adapt to a future potential respiratory virus. We are focused on completing human trials and delivering vaccines in 2022."

"Combining our RNA technology with ImmunityBio's expertise and access has the potential to significantly accelerate and de-risk our time to market for a much-needed second generation COVID-19 vaccine," said John Melo, President and Chief Executive Officer of Amyris. "We are very pleased with the progress our teams have made in the short time we've been working together and remain focused on completing successful human trials as quickly as possible."

"Two years into the COVID-19 pandemic, it has become abundantly clear that next-generation vaccines will be required to put the pandemic behind us," said Corey Casper, M.D., MPH and Chief Executive Officer of IDRI. "Vaccines that are accessible to every person across the globe, broad in their protection against current and future variants of concern, and invoke durable protective immunity are now within our reach. The ability to 'mix and match' vaccine platforms through this new joint venture and ImmunityBio's multiple COVID vaccine platforms represents one of the most exciting approaches to ending COVID-19."

Further announcements will be made when results of human trials are available."

[north40000]

https://ih.advfn.com/stock-market/NASDAQ/amyris-AMRS/stock-news/86883779/amyris-and-minerva-foods-complete-joint-venture-an

"EMERYVILLE, Calif., Dec. 23, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the completion of a previously announced joint venture agreement with MF 92 VENTURES LLC ("Minerva"), a Minerva Foods subsidiary, to develop molecules for the sustainable production and distribution of animal protein ("the Joint Venture").

The Joint Venture between Amyris and Minerva will be focused on enhancing the sustainability of the Brazilian meat exporting market, which is the largest in the world. Minerva and Amyris will collaborate on the development, scale-up and production of new target molecules, which Minerva will fund and bring to market commercially. The new molecules will target several sustainability objectives, including improving and lowering the carbon intensity of producing animal protein; sustainable packaging; and fermentation-based, natural preservatives that facilitate the transport of meat around the world. Additionally, the parties expect to work on the production of fermentation-based protein as an alternative to animal-based protein.

Relevant regulatory approvals have been attained for the development and scale-up of a vertical technology and commercialization platform that aims to transform the way protein is produced. The Joint Venture is expected to generate first license revenue for Amyris before the end of 2021 and deliver first commercial production of its initial targets in 2022.

"We are very pleased to partner with Amyris, the leader in synthetic biotechnology and the world's leading fermentation technology company," said Fernando Galletti De Queiroz, Chief Executive Officer of Minerva. "We have a strong track record of commercializing innovative technologies for producing animal protein and reducing carbon emissions. With Amyris' clean fermentation technology, we expect to lead the disruption of the animal protein industry and reduce our industry's carbon footprint."

"We are excited to further expand the reach of our technology and manufacturing expertise through our partnership with Minerva Foods. We believe this collaboration will accelerate the commercialization of natural, sustainably produced molecules that are capable of transforming the production and supply chain of animal protein," commented John Melo, President and Chief Executive Officer of Amyris. "We have a proven track record in biotechnology of developing and scaling molecules that are transforming several vertical markets. We are executing well and are on track for a strong fourth quarter."[more]

[BottomBounce]

$AMRS Watching Amyris, Akoustis Technologies, Gevo; Traders Circulate TipRanks Article '3 "Strong Buy" Stocks Under $10 That Are Poised for a Breakout Year'
https://www.tipranks.com/news/article/3-strong-buy-stocks-under-10-that-are-poised-for-a-breakout-year/

[kx500rider]

The CEO should be fired!
Just no excuse for his incompetence.
The institutional investors must be pissed. There was a lot of them. Maybe they are all gone now.

[westjtter]

Their new financing announced today is the cause of the share price decline. While it may impact the short term share price, I believe once the deal is formally consummated the share price will start to recover!

Again, while short term this may cause some pain, for the company to grow and expand further, they had to secure solid funding. I like the vehicle they chose and so we now just await exact details as the the capped call and interest rate.

In any event, I see things looking a whole lot better within 3 to 4 months so hang in there.

[samsamsamiam]

https://www.sec.gov/litigation/admin/2021/34-93341.pdf

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION
SECURITIES EXCHANGE ACT OF 1934 Re le ase No. 93341 / October 15, 2021
ACCOUNTING AND AUDITING ENFORCEMENT Re le ase No. 4264 / October 15, 2021
ADMINISTRATIVE PROCEEDING File No. 3-20624
In the Matter of AMYRIS, INC.,
Respondent.
ORDER INSTITUTING CEASE-AND- DESIST PROCEEDINGS PURSUANT TO SECTION 21C OF THE SECURITIES EXCHANGE ACT OF 1934, MAKING FINDINGS, AND IMPOSING A CEASE- AND-DESIST ORDER
I.
The Securities and Exchange Commission (“Commission”) deems it appropriate that cease- and-desist proceedings be, and hereby are, instituted pursuant to Section 21C of the Securities Exchange Act of 1934 (“Exchange Act”), against Amyris, Inc. (“Amyris” or “Respondent”).
II.
In anticipation of the institution of these proceedings, Respondent has submitted an Offer of Settlement (the “Offer”) which the Commission has determined to accept. Solely for the purpose of these proceedings and any other proceedings brought by or on behalf of the Commission, or to which the Commission is a party, and without admitting or denying the findings herein, except as to the Commission’s jurisdiction over it and the subject matter of these proceedings, which are admitted, Respondent consents to the entry of this Order Instituting Cease- And-Desist Proceedings Pursuant To Section 21C Of The Securities Exchange Act Of 1934, Making Findings, And Imposing A Cease-And-Desist Order (“Order”), as set forth below.

III.
On the basis of this Order and Respondent’s Offer, the Commission finds1 that:
Summary
1. During the first two quarters of 2018, Amyris improperly recognized certain royalty revenues that rendered its financial statements materially inaccurate. These revenue recognition errors resulted from internal accounting control failures that led to important information not being communicated to the company’s internal accounting staff concerning certain significant royalty payments, which also resulted in Amyris’s failure to make and keep accurate books and records.
2. Amyris failed to devise internal accounting controls to provide reasonable assurance that relevant information was communicated to its accounting staff so that transactions, including the estimation of royalty revenue could be recorded in accordance with U.S. generally accepted accounting principles (“GAAP”). Amyris also lacked sufficient resources within its finance and accounting function to provide reasonable assurance that the company properly applied GAAP to its royalty revenue transactions.
3. As a consequence of Amyris’s control insufficiencies, it overstated its royalty revenues in the first two quarters of 2018, rendering the company’s financial statements materially inaccurate and leading to the Company’s restatement of its quarterly revenue results for the first three quarters of 2018. As a result of this conduct, Amyris violated Sections 13(a), 13(b)(2)(A), and 13(b)(2)(B) of the Exchange Act and Rules 13a-11 and 13a-13 thereunde



More…

[tavito]

Seems ready, or very close to it. Let’s Go!!

[historyperson]

New to researching this company. So in about 5 years AMRS will make investors rich? Is that the rough sentiment?

[north40000]

Now see Andrew Bary article (re the large potential Amyris has) in Barron’s titled “How Synthetic Biology Could Become a Huge Industry”, per Dow Jones PR dated 7/16/2021. The article covers all current Amyris product lines(print edition dated this past weekend).

[timmuggs]

New info on Amyris:

This Seeking Alpha article basically just links to a Youtube interview with Randy Baron, an analyst in the biotech field. It's really good. He talks a lot about AMRS, their product segments, their strategy, and their CEO. Well worth a listen. AMRS is generating revenue from cosmetics, sugar substitutes, and cannabinoids, raw materials are all made in house via biotech.

https://seekingalpha.com/article/4436940-amyris-how-lead-in-synthetic-biology-could-brew-up-big-profits


This 2nd piece talks about an acquisition (Olika) that will add value to another recent acquisition, Pippette, which specializes in baby care skin products.
https://seekingalpha.com/news/3706424-amyris-expands-with-acquisition-of-olika-consumer-brand

What's the business rationale for AMRS to acquire these small brands? I'm guessing there are two/three:

- They can use their own squalane products in them, which makes them richer while reducing costs, as AMRS makes the squalene.

- Like other companies in consumer goods space, sales costs are reduced the more similar products you have to put on the shelf, or in the website.

- When these products grow, a company like P&G starts looking at acquiring. AMRS is structure so they could spin off products & cash in. I'm thinking Biossance, Pippette, Olika, in skin care, and Purecane as a sugar substitute perhaps attractive to companies in that sector. Not to mention their essences and flavors.

As an example, Biossance, a business unit of AMRS, is growing very rapidly in high end skincare based on their squalene. They can afford to use a much richer dose than the high end brands, because they source it from an acre of sugar cane they grow in Brazil, rather than killing 2 million sharks a year, the estimated supply chain for high end cosmetics.
Have a look: https://biossance.com

BTW, AMRS is listed on IHub as in the biofuels segment. That's very old news. Fracking killed that market opportunity, which forced AMRS to focus on their skills in identifying specific molecules and then finding ways to grow them in commercial quantities. They have since expanded into CBD/CBG, squalene (a chemical derived from shark liver that they can make without killing sharks - used extensively in very high end cosmetics), identifying molecules that give specific tastes, flavors & aromas. AMRS is busy expanding businesses that take advantage of their basic skills from their roots as a biotech innovator.

I hope others on iHub will have a look at the new directions in AMRS.

[Street Smart]

agree. plenty for everyone especially the first ones

[PSea]

no concern. let's see how they do w/ strain optimization.

...and let's see if their technology infringes amrs ip.

plus, if both turn out ok, this market is going to grow multiples. plenty for everyone.

[Street Smart]

yes it all means dilution and share selling

[Street Smart]

Looks like Amyris has a competitor in team of Ginkgos. cron .altria for CBG. Although its in high demand and rare I thin both will cash in big

[CASHFISHIN]

Good News!!!
Amyris And Ingredion Partner To Manufacture And Market Sugar Reduction And Fermentation-based Food Ingredients

[CASHFISHIN]

Financials coming out May 6th.

[CASHFISHIN]

Looks like AMRS are trying to get alot more aquisitions these days.
Positive for AMRS!!! in my opinion.

[north40000]

AMRS:

https://seekingalpha.com/article/4417066-amyris-is-strengthening-lead-in-next-industrial-revolution

[ClayTrader]

* * $AMRS Video Chart 04-08-2021 * *

Link to Video - click here to watch the technical chart video

[north40000]

It is odd, isn’t it. Price targets seem to be about the same. With U.S., Europe and China markets and populations in the picture for AMRN by end of 2021, one would think AMRN would be trending much higher than $6+ by now.

[PSea]

if only AMRN could perform as well.

[SubstitutedPinions]

https://stockinvest.us/stock/AMRS

[CASHFISHIN]

100% BUY ON BARCHART!!!
AMRS!!!

[CASHFISHIN]

I agree, this is a gold mine.
AMRS!!!

[north40000]

Purecane, subsidiary of AMRS, named one of Fastmoney’s most innovative companies of 2021.

[ClayTrader]

* * $AMRS Video Chart 03-02-2021 * *

Link to Video - click here to watch the technical chart video

[PSea]

LOVE that no one is posting here. This company is an undiscovered GOLD MINE!

[CASHFISHIN]

AMRS is a 100% buy on Barchart!!!
Keep an eye on this one. IMO
AMRS!!!

[ClayTrader]

* * $AMRS Video Chart 01-07-2021 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $AMRS Video Chart 12-16-2020 * *

Link to Video - click here to watch the technical chart video

[north40000]

SEPHORA and KOHL’s announce that 825 mini-SEPHORA stores will be placed within, at the front of, KOHL’s locations, per interview of KOHL’s CEO on CNBC-TV.
Amyris sells branded beauty products to SEPHORA.